Literature DB >> 24436229

Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction.

Jiake He1, Yang Yu, Bhagwat Prasad, Xijing Chen, Jashvant D Unadkat.   

Abstract

An unusual, but clinically significant, digoxin (DIG)-bupropion (BUP) drug interaction (DDI), in which BUP increased DIG renal clearance by 80% is reported. To investigate the mechanism(s) of this unusual DDI, first the effect of BUP, its circulating metabolites or their combination on [(3) H]-DIG transport by cells expressing human P-gp or human OATP4C1 was determined. Second, the study asked whether this DDI could be replicated in the rat so that it could be used to conduct mechanistic studies. Then, the effect of BUP and its rat metabolites on [(3) H]-DIG transport were tested by cells expressing rat Oatp4c1. Bupropion and its metabolites had no effect on human P-gp mediated transepithelial transport of [(3) H]-DIG. Bupropion and hydroxybupropion (HBUP) significantly stimulated H-OATP4C1 mediated transport of [(3) H]-DIG. In addition, BUP cocktail (BUP plus its metabolites) significantly increased the H-OATP4C1 mediated transport of [(3) H]-DIG, and partially reversed the inhibition by 100 µm DIG. However, erythro-hydrobupropion (EBUP) and threo-hydrobupropion (TBUP) did not affect the [(3) H]-DIG uptake by H-OATP4C1 cells. Bupropion administration significantly increased digoxin renal clearance in rats. Surprisingly, bupropion significantly inhibited r-Oatp4c1 mediated transport of [(3) H]-DIG at clinically relevant unbound plasma concentrations of BUP or those observed in the rat study, while HBUP or TBUP did not. These data support our hypothesis that at clinically relevant plasma concentrations, bupropion and its metabolites activate H-OATP4C1 mediated DIG tubular secretion, and could possibly explain the increase in digoxin renal clearance produced by bupropion. While bupropion increased digoxin renal clearance in the rat, it appeared to do so by inhibiting r-Oatp4c1-mediated digoxin renal reabsorption.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  H-OATP4C1/r-Oatp4c1; P-gp; bupropion; digoxin; drug-drug interaction

Mesh:

Substances:

Year:  2014        PMID: 24436229     DOI: 10.1002/bdd.1890

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  7 in total

1.  Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys.

Authors:  Yang Shen; Yang Yu; Wei Lai; Shuai Li; Zixuan Xu; Jiejing Jin; Xia Yan; Han Xing; Xijing Chen; Aizhen Xiong; Chunhua Xia; Jiake He; Kui Hong
Journal:  Pharm Res       Date:  2018-11-06       Impact factor: 4.200

Review 2.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.

Authors:  Daniel Scotcher; Christopher R Jones; Aleksandra Galetin; Amin Rostami-Hodjegan
Journal:  J Pharmacol Exp Ther       Date:  2017-01-05       Impact factor: 4.030

5.  Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin.

Authors:  Chih-Hsuan Hsin; Marc S Stoffel; Malaz Gazzaz; Elke Schaeffeler; Matthias Schwab; Uwe Fuhr; Max Taubert
Journal:  Sci Rep       Date:  2020-07-27       Impact factor: 4.379

6.  The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine.

Authors:  Emir Taghikhani; Renke Maas; Martin F Fromm; Jörg König
Journal:  PLoS One       Date:  2019-03-13       Impact factor: 3.240

7.  Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail.

Authors:  Marija Bosilkovska; Gaelle Magliocco; Jules Desmeules; Caroline Samer; Youssef Daali
Journal:  J Pers Med       Date:  2019-10-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.